Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-SPECT CVT: Dabigatran vs Warfarin in Cerebral Venous Thrombosis
NCT02913326Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2016
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of dabigatran in Cerebral venous thrombosis (CVT) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Composite of Venous Thrombotic Event (VTE) or Major Bleeding Event (MBE) at 25 weeks. Started Dec 2016; status: completed.
02
Drugs
dabigatran
03
Conditions
Cerebral venous thrombosis (CVT)
Beyond the preview
Go deeper on NCT02913326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02913326.